A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy

British Journal of Pharmacology

Volumn 164, Issue 1, 2011, Pages 159-169

  Mixcoatl Zecuatl, T ^a   Jolivalt, C G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 HT 2A receptor; diabetes; duloxetine; spinal cord; tactile allodynia

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; DULOXETINE; KETANSERIN; PRUVANSERIN; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; NERVE FIBER; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

AMPHETAMINES; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; FEMALE; HYPERALGESIA; KETANSERIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; THIOPHENES;

EID: 79961214216     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01334.x     Document Type: Article

References (65)

1. Adamec R, Creamer K, Bartoszyk GD, Burton P, (2004). Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats. Eur J Pharmacol 504: 79-96. (Pubitemid 39410726)
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br. J. Pharmacol 158 (Suppl. 1): S1-S254.
3. Anjaneyulu M, Chopra K, (2004). Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice. Eur J Pharmacol 497: 285-292. (Pubitemid 39164893)
4. Bardin L, Schmidt J, Alloui A, Eschalier A, (2000). Effect of intrathecal administration of serotonin in chronic pain models in rats. Eur J Pharmacol 409: 37-43.
5. Bartoszyk GD, van Amsterdam C, Bottcher H, Seyfried CA, (2003). EMD 281014, a new selective serotonin 5-HT2A receptor antagonist. Eur J Pharmacol 473: 229-230. (Pubitemid 36929889)
6. Benditt EP, Holcenberg H, Lagunoff D, (1963). The role of serotonin (5-hydroxytryptamine) in mast cells. Ann N Y Acad Sci 103: 179-184.
7. Bomholt SF, Mikkelsen JD, Blackburn-Munro G, (2005). Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 48: 252-263. (Pubitemid 40208261)
8. Boulton AJ, Armstrong WD, Scarpello JH, Ward JD, (1983). The natural history of painful diabetic neuropathy-a 4-year study. Postgrad Med J 59: 556-559. (Pubitemid 13005878)
9. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF, (2005). Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39: 43-53. (Pubitemid 39422285)
10. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al,. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-880. (Pubitemid 34031892)
11. Calcutt NA, (2004). Experimental models of painful diabetic neuropathy. J Neurol Sci 220: 137-139. (Pubitemid 38622115)
12. Calcutt NA, Backonja MM, (2007). Pathogenesis of pain in peripheral diabetic neuropathy. Curr Diab Rep 7: 429-434. (Pubitemid 350284973)
13. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR, (1996). Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 68: 293-299. (Pubitemid 27025887)
14. Cameron NE, Eaton SE, Cotter MA, Tesfaye S, (2001). Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44: 1973-1988. (Pubitemid 33124042)
15. Carlton SM, Coggeshall RE, (1997). Immunohistochemical localization of 5-HT2A receptors in peripheral sensory axons in rat glabrous skin. Brain Res 763: 271-275. (Pubitemid 27364450)
16. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL, (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63. (Pubitemid 24238751)
17. Chen SR, Pan HL, (2001). Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats. Anesthesiology 95: 525-530.
18. Dogrul A, Seyrek M, (2006). Systemic morphine produce antinociception mediated by spinal 5-HT7, but not 5-HT1A and 5-HT2 receptors in the spinal cord. Br J Pharmacol 149: 498-505. (Pubitemid 44658510)
19. Dray A, (1995). Inflammatory mediators of pain. Br J Anaesth 75: 125-131.
20. Dubner R, Ren K, (1999). Endogenous mechanisms of sensory modulation. Pain (Suppl. 6): S45-S53.
21. Eide PK, Hole K, (1993). The role of 5-hydroxytryptamine (5-HT) receptor subtypes and plasticity in the 5-HT systems in the regulation of nociceptive sensitivity. Cephalalgia 13: 75-85. (Pubitemid 23116115)
22. Engleman EA, Perry KW, Mayle DA, Wong DT, (1995). Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 12: 287-295.
23. Gaietta GM, Yoder EJ, Deerinck T, Kinder K, Hanono A, Han A, et al,. (2003). 5-HT2a receptors in rat sciatic nerves and Schwann cell cultures. J Neurocytol 32: 373-380. (Pubitemid 38197817)
24. Glassman AB, (1993). Platelet abnormalities in diabetes mellitus. Ann Clin Lab Sci 23: 47-50. (Pubitemid 23051337)
25. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S, (2005). Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116: 109-118. (Pubitemid 40828506)
26. Honda M, Uchida K, Tanabe M, Ono H, (2006). Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors. Neuropharmacology 51: 866-872. (Pubitemid 44286938)
27. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al,. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157-203. (Pubitemid 24185150)
28. Ikeda T, Ishida Y, Naono R, Takeda R, Abe H, Nakamura T, et al,. (2009). Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. Neurosci Res 63: 42-46.
29. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM, (2004). Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311: 576-584. (Pubitemid 39391542)
30. Jones CK, Peters SC, Shannon HE, (2005). Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 312: 726-732. (Pubitemid 40189572)
31. Joshi SK, Hernandez G, Mikusa JP, Zhu CZ, Zhong C, Salyers A, et al,. (2006). Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity. Neuroscience 143: 587-596. (Pubitemid 44716595)
32. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, et al,. (2003). Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45: 935-944. (Pubitemid 37297919)
33. Kuhad A, Bishnoi M, Chopra K, (2009). Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain. Indian J Exp Biol 47: 193-197.
34. Lunn MP, Hughes RA, Wiffen PJ, (2009). Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 4: CD007115.
35. Malmberg AB, Yaksh TL, Calcutt NA, (1993). Anti-nociceptive effects of the GM1 ganglioside derivative AGF 44 on the formalin test in normal and streptozotocin-diabetic rats. Neurosci Lett 161: 45-48. (Pubitemid 23311061)
36. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, et al,. (1994). Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 75: 569-576. (Pubitemid 24267340)
37. Martin GR, (1994). Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther 62: 283-324. (Pubitemid 24248421)
38. Mbaki Y, Ramage AG, (2008). Investigation of the role of 5-HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat. Br J Pharmacol 155: 343-356.
39. Millan MJ, (1999). The induction of pain: an integrative review. Prog Neurobiol 57: 1-164. (Pubitemid 28551764)
40. Millan MJ, (2002). Descending control of pain. Prog Neurobiol 66: 355-474. (Pubitemid 34606906)
41. Munro G, (2009). Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations. Eur J Pharmacol 605: 95-102.
42. Nitanda A, Yasunami N, Tokumo K, Fujii H, Hirai T, Nishio H, (2005). Contribution of the peripheral 5-HT 2A receptor to mechanical hyperalgesia in a rat model of neuropathic pain. Neurochem Int 47: 394-400. (Pubitemid 41242620)
43. Nordlind K, Azmitia EC, Slominski A, (2008). The skin as a mirror of the soul: exploring the possible roles of serotonin. Exp Dermatol 17: 301-311. (Pubitemid 351338673)
44. Obata H, Saito S, Ishizaki K, Goto F, (2000). Antinociception in rat by sarpogrelate, a selective 5-HT(2A) receptor antagonist, is peripheral. Eur J Pharmacol 404: 95-102.
45. Obata H, Saito S, Sasaki M, Ishizaki K, Goto F, (2001). Antiallodynic effect of intrathecally administered 5-HT(2) agonists in rats with nerve ligation. Pain 90: 173-179. (Pubitemid 32146571)
46. Okamoto K, Imbe H, Morikawa Y, Itoh M, Sekimoto M, Nemoto K, et al,. (2002). 5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. Pain 99: 133-143. (Pubitemid 35247536)
47. Padayatti PS, Paulose CS, (1999). Alpha2 adrenergic and high affinity serotonergic receptor changes in the brain stem of streptozotocin-induced diabetic rats. Life Sci 65: 403-414. (Pubitemid 29325283)
48. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M, (1995). Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 89-94.
49. Perahia DG, Pritchett YL, Desaiah D, Raskin J, (2006). Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 21: 311-317. (Pubitemid 44498273)
50. Piesla MJ, Leventhal L, Strassle BW, Harrison JE, Cummons TA, Lu P, et al,. (2009). Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. Brain Res 1295: 89-98.
51. Pietraszek MH, Takada Y, Takada A, Fujita M, Watanabe I, Taminato A, et al,. (1992). Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 66: 765-774.
52. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, et al,. (2005). A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6: 346-356. (Pubitemid 41727332)
53. Sandrini M, Vitale G, Vergoni AV, Ottani A, Bertolini A, (1997). Streptozotocin-induced diabetes provokes changes in serotonin concentration and on 5-HT1A and 5-HT2 receptors in the rat brain. Life Sci 60: 1393-1397. (Pubitemid 27191934)
54. Sasaki M, Ishizaki K, Obata H, Goto F, (2001). Effects of 5-HT2 and 5-HT3 receptors on the modulation of nociceptive transmission in rat spinal cord according to the formalin test. Eur J Pharmacol 424: 45-52. (Pubitemid 32695553)
55. Sjoerdsma A, Waalkes TP, Weissbach H, (1957). Serotonin and histamine in mast cells. Science 125: 1202-1203.
56. Tallarida RJ, Murray RB, (1981). Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag: New York; Heidelberg; Berlin.
57. Thor KB, Kirby M, Viktrup L, (2007). Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 61: 1349-1355. (Pubitemid 47052367)
58. Tsukamoto M, Kiso T, Shimoshige Y, Aoki T, Matsuoka N, (2010). Spinal mechanism of standard analgesics: evaluation using mouse models of allodynia. Eur J Pharmacol 634: 40-45.
59. Van Steenwinckel J, Noghero A, Thibault K, Brisorgueil MJ, Fischer J, Conrath M, (2009). The 5-HT2A receptor is mainly expressed in nociceptive sensory neurons in rat lumbar dorsal root ganglia. Neuroscience 161: 838-846.
60. Vranken JH, Hollmann MW, van der Vegt MH, Kruis MR, Heesen M, Vos K, et al,. (2011). Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial. Pain 152: 267-273.
61. Wang SY, Calderon J, Kuo Wang G, (2010). Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology 113: 655-665.
62. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al,. (2006). A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67: 1411-1420. (Pubitemid 44632065)
63. Yaksh TL, Rudy TA, (1976). Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17: 1031-1036. (Pubitemid 8063691)
64. Yoder EJ, Tamir H, Ellisman MH, (1997). Serotonin receptors expressed by myelinating Schwann cells in rat sciatic nerve. Brain Res 753: 299-308. (Pubitemid 27151875)
65. Ziegler D, (2009). Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care 32 (Suppl. 2): S414-S419.